Je was op zoek naar: hydroxyurea (Engels - Maltees)

prior hydroxyurea
ingħataw hydroxyurea qabel

prior hydroxyurea prior interferon prior bone marrow transplant
(il- 25- il- 75 perċentwali) ingħataw hydroxyurea qabel ingħataw interferon qabel kellhom trapjant tal- mudullun qabel

it may be given with hydroxyurea or anagrelide if clinically indicated.
huwa jista’ jingħata ma’ hydroxyurea jew anagrelide jekk ikun indikat b’mod kliniku.

no inhibition of deferasirox metabolism by hydroxyurea was observed in vitro.
ma deherx li kien hemm impediment ta’ metaboliżmu ta’ deferasirox minn hydroxyurea in vitro.

hence, hydroxyurea should not be used in the treatment of hiv infection.
għalhekk, hydroxyurea m' għandux jintuża fil- kura ta 'l- infezzjoni ta' l - hiv.

to compare the average time to response following treatment with anagrelide or hydroxyurea.
sabiex jiġu mqabbla l- ħinijiet medji ta 'respons wara trattament b' anagrelide jew hydroxyurea.

when introna is used with hydroxyurea, the frequency and severity of cutaneous vasculitis may be increased.
meta introna jintuża ma ’ hydroxyurea, il- frekwenza u s- severità ta ’ vaskulite kutanja jistgħu jiżdiedu.

to compare the cytoreductive impact of anagrelide and hydroxyurea on white blood cell and red blood cell lines.
sabiex jiġi mqabbel l- impatt ċitoriduttiv ta 'anagrelide u hydroxyurea fuq ir- razez ta' ċelloli bojod u ċelloli ħomor.

to compare the efficacy of anagrelide and hydroxyurea in terms of the number of patients achieving a complete response.
sabiex tiġi mqabbla l- effikaċja ta 'anagrelide u hydroxurea f' termini ta' l- għadd ta 'pazjenti li jkollhom respons komplet.

most of these patients had histories of extended treatment with hydroxyurea and prior nmsc or pre-malignant skin lesions.
il- biċċa l-kbira ta’ dawn il-pazjenti kellhom stejjer ta’ trattament estiż b’hydroxyurea u nmsc preċedenti jew leżjonijiet tal-ġilda pre-malinji.

in polycythaemia vera, jakavi was studied in one main study which involved 222 patients who were resistant or intolerant to treatment with hydroxyurea.
fil-poliċitemija vera, jakavi ġie studjat fi studju ewlieni wieħed li involva 222 pazjent li rreżistew jew ma ttollerawx il-kura b'hydroxyurea.

in polycythaemia vera the chmp considered that jakavi is of benefit to patients who do not respond or are intolerant to treatment with hydroxyurea, while the safety profile is acceptable.
fil-poliċitemija vera, is-chmp ikkunsidra li jakavi huwa ta' benefiċċju għall-pazjenti li ma jirrispondux jew ma jittollerawx il-kura b'hydroxyurea, filwaqt li l-profil ta' sigurtà huwa aċċettabbli.

a phase iiib, randomised study to compare the efficacy, tolerability and safety of anagrelide hydrochloride versus hydroxyurea in high-risk patients with essential thrombocythaemia.
studju ta 'fażi iiib, li fih il- pazjenti ntgħażlu bl- addoċc sabiex iqabbel l- effikaċja, it - tollerabilità u s- sigurtà ta' anagrelide

to compare the safety of anagrelide and hydroxyurea in short and long term usage of up to three years with particular reference to cardiovascular safety (as assessed by echocardiography).
sabiex tiġi mqabbla s- sigurtà ta 'anagrelide u hydroxyurea meta jintużaw fuq perijodu qasir u fit - tul sa tliet snin b' referenza partikolari għas- sigurà kardjovaskulari (kif assessjat b' ekokardjografija).

hepatotoxicity and hepatic failure resulting in death were reported during postmarketing surveillance in hiv infected patients treated with antiretroviral agents and hydroxyurea; fatal hepatic events were reported most often in patients treated with stavudine, hydroxyurea and didanosine.
epatotossiċità u falliment tal- fwied li rriżultaw f' mewt ġew irrappurtati waqt is- sorveljanza ta 'wara l- bejgħ f' pazjenti infettati bl- hiv ikkurati b' mediċini antiretrovirali u hydroxyurea; każijiet fatali tal- fwied ġew irrappurtati kemm- il darba f' pazjenti kkurati bi stavudine, hydroxyurea u didanosine.

hydroxycarbamide, which used to be known as hydroxyurea, has been available in the european union (eu) for several decades for use in other illnesses, including some types of cancer.
hydroxycarbamide, li qabel kien magħruf bħala hydroxyurea, ilu disponibbli fl- unjoni ewropea (ue) għal diversi għexieren ta ’ snin sabiex jintuża għal mardiet oħra, inkluż xi tipi ta 'kankru.

the majority of patients had a long history of cml that included extensive prior treatment with other antineoplastic agents, including imatinib, hydroxyurea, interferon, and some had even failed organ transplant (table 9).
il-maġġoranza tal-pazjenti kellhom passat twil ta’ cml li kien jinkludi kura estensiva minn qabel b’sustanzi antineoplastiċi oħrajn, inkluż imatinib, hydroxyurea, interferon, u xi wħud li kienu saħansitra tilfu trapjant ta’ organu (tabella 9).